ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines

  22 November 2023  PHN Immunisation Support Program   |   Third party content – view disclaimer

The Australian Technical Advisory Group on Immunisation (ATAGI) advises that the monovalent Omicron XBB.1.5 vaccines are now the preferred COVID-19 vaccines for children aged 5 years or older and adults receiving primary or further COVID-19 doses, as outlined in the Australian Immunisation Handbook (Handbook).

For individuals who have received the recommended 2023 doses, no further doses or re-vaccination with XBB.1.5-containing vaccines is recommended. With an increase in COVID-19 cases since November 2023, ATAGI encourages all persons who have not received the recommended 2023 dose/s to receive them as soon as possible.

The Pfizer monovalent Omicron XBB.1.5 vaccines are available in the 5 to <12 years formulation (light blue cap) and the ≥12 years formulation (dark grey cap). The Moderna monovalent Omicron XBB.1.5 vaccine is registered for individuals aged 12 years and older.

There is no monovalent XBB.1.5-containing vaccines registered for use children aged 6 months to 4 years The Pfizer original (maroon cap) is the only formulation available in this age group.

The COVID-19 chapter in the Handbook details which vaccines are recommended for which age group.

The full ATAGI statement is available on the Department of Health and Aged Care website.

Disclaimer: This article was provided by PHN Immunisation Support Program. While every effort has been made to ensure the information is accurate, North Western Melbourne Primary Health Network does not warrant or represent the accuracy, currency and completeness of any information or material included within.